Trade Dyne Therapeutics, Inc. - DYN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$4.32)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.13)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$4.32)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.13)

Key Stats

• Prev. Close: 24.88
• Open: 24.33
• 1-Year Change: 81.3%
• Day's Range: 24.16 - 24.44

Trade Dyne Therapeutics, Inc. - DYN

About Dyne Therapeutics Inc

Dyne Therapeutics Inc. is building a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. With its FORCE platform, it has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Dyne Therapeutics Inc revenues was not reported. Net loss increased from $59.4M to $149.3M. Higher net loss reflects Research and de increase from $35.4M to $97.8M (expense), Labor & Related Expenses in R&D increase from $7.1M to $16.2M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense).